Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Drug industry

Article Abstract:

Multinational corporations with good market capitalization, revenues, and earnings helped the drug industry achieve an earnings increase of 14.8% in 1996, and the first half of 1997 could see a better increase. Eli Lilly and ten other research-based multinationals saw their market capitalization grow 29% since May 1997 and 73.2% since Aug 1996. However, drug company stocks may have high valuations under market conditions and competition in 1997.

Author: Clark, Charles, Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Maher, John E., daSilva, Mark W., Smith, Reid, Gagas, Adam C.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1997
SmithKline Beecham PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Drug industry

Article Abstract:

The drug industry is doing well during 1997, with a 15% earnings increase per year for multinational firms. Investors with capital are fond of drug companies, especially large research firms. Those investors looking for drug equities should realize that many firms are appreciably high in terms of valuations. Caution is needed to select from these group, despite the high earnings growth.

Author: Clark, Charles, Gallen, David, Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Maher, John E., Gagas, Adam C., daSilva, Mark M.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1997
Economic aspects, SmithKline Beecham Corp. (Philadelphia, Pennsylvania), SBH, Quintiles Transnational Corp., QTRN

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Pharmaceutical industry, Drugs, Finance, Eli Lilly and Co., Pfizer Inc., Pharmacia and Upjohn Inc., PNU, Glaxo Wellcome PLC, Genentech Inc., Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Block Drug Company Inc., Chiron Corp., Cygnus Inc., Dura Pharmaceuticals Inc., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., Sicor Inc., Watson Pharmaceuticals Inc., AZA, AHP, AMGN, BGEN, BLOCA, BMY, CHIR, DURA, FRX, GENZ, ICN, IMNX, IVX, LLY, MLY, PRGO, PFE, SGP, WLA, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Rhone-Poulenc Rorer Inc., Neurex Corp., Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, SHR, WATS
Similar abstracts:
  • Abstracts: Precious metals. inVentiv Health Inc
  • Abstracts: Drug industry. Barr Pharm., Inc
  • Abstracts: Drug industry. Bristol-Myers Sq
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.